Renal tubular acidosis and acute kidney injury secondary to cemiplimab

Rashidi, Arash; Herlitz, Leal; Tariq, Hafsa

doi:10.1177/23993693211012706

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was treated with glucocorticoids and his renal function improved. After 3 months his serum creatinine level was 1.47 mg/dL [ 83 ]. Renal AEs caused by treatment with ICIs are summarized in Table 3 .…”

Section: Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific antibodies and cytokine therapy improve patients’ outcomes. However, stimulation of the immune system, beneficial in terms of fighting against cancer, generates the risk of harm to other cells in a patient’s body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, superficially, are renal AEs in patients treated with ICIs. International guidelines issued by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are fewer data concerning real occurrence and possible presentations of renal adverse drug reactions of other immunotherapeutic methods. This implies the need for the collection of safety data during ongoing clinical trials and in the real-life world to characterize the hazard related to the use of new immunotherapies and management of irAEs.

show abstract

Section: Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The patient was treated with glucocorticoids and his renal function improved. After 3 months his serum creatinine level was 1.47 mg/dL [84]. AEs: adverse events, CTLA-4: cytotoxic T-lymphocyte-associated protein 4, PD1: programmed cell death protein 1, PD-L1: programmed death-ligand 1.…”

Section: Occurrence and Specific Nephrotoxicitiesmentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka¹,

Łącki-Zynzeling²,

Nicze³

et al. 2022

Preprint

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhib-itors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines and bispecific an-tibodies are improving patients’ outcomes. However, stimulation of the immune system, benefi-cial in terms of fighting against cancer, generates the risk of harm to other cells in a patient's body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, su-perficially, are renal AEs in patients treated with ICIs. International guidelines issued by Euro-pean Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are scarce data concerning renal adverse drug reactions of other immunotherapeutic methods. This implicates the need for the collection of safety data during ongoing clinical trials and in the re-al-life world to characterize the hazard related to the use of new immunotherapies and manage-ment of irAEs.

show abstract